Jonathan Orme

发表

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

I. Barrett, K. Varnäs, K. Valerie, 2018, Science Advances.

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Paul D. Smith, B. Cho, Matthew J. Martin, 2020, Molecular Cancer Therapeutics.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

J. Riess, D. Gandara, J. Keck, 2018, Molecular Cancer Therapeutics.

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.

Fiona Pachl, A. Pike, M. O’Connor, 2021, Journal of medicinal chemistry.

Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation

Paul D. Smith, D. Hargreaves, Matthew J. Martin, 2019, Cancer Chemistry.

Cellular Assay Optimization

David I. Fisher, K. Roberts, Jonathan P. Orme, 2011, Journal of biomolecular screening.

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Fiona Pachl, M. O’Connor, Glen Hawthorne, 2018, Experimental and Molecular Therapeutics.

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

E. Hennessy, C. Chuaqui, J. Debreczeni, 2016, ACS medicinal chemistry letters.

CLANet: A Comprehensive Framework for Cross-Batch Cell Line Identification Using Brightfield Images

A. Corrigan, Yinhai Wang, Lei Tong, 2023, ArXiv.

Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR

E. Evertsson, J. Kettle, A. Argyrou, 2024, ACS Medicinal Chemistry Letters.

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.

Paul D. Smith, Michal Bista, D. Hargreaves, 2021, Journal of medicinal chemistry.